Hepatology

Journal Abbreviation: HEPATOLOGY
ISSN: 0270-9139
Publisher: Wiley-Blackwell

Publications (22)

close-button

Types of publications

Journal article
Unpublished / Preprint

Publication year

From
To

Abstract

EXPERT CONSENSUS CRITERIA AND PRACTICAL RECOMMENDATIONS FOR PBC CARE IN THE COVID-19 ERA AND BEYOND (2021) Berenguer M, Kremer A, Hirschfield G, Jones D, Leroy V, Adekunle F, Carbone M Conference contribution LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PRIMARY BILIARY CHOLANGITIS: RESPONDER ANALYSIS OF OVER 5 YEARS OF TREATMENT IN THE POISE TRIAL (2020) Hansen BE, Jones D, Carbone M, Bowlus CL, Nevens F, Kremer A, Liberman A, et al. Conference contribution LONG-TERM EFFICACY AND SAFETY OF OBETICHOLIC ACID IN PATIENTS WITH PBC FROM THE POISE TRIAL GROUPED BIOCHEMICALLY BY RISK OF DISEASE PROGRESSION (2020) Bowlus CL, Trauner MH, Kremer A, Liberman A, Malecha ES, Macconell L, Nevens F Conference contribution Genetic Variation in HSD17B13 Reduces the Risk of Developing Cirrhosis and Hepatocellular Carcinoma in Alcohol Misusers (2020) Stickel F, Lutz P, Buch S, Nischalke HD, Silva I, Rausch V, Fischer J, et al. Journal article THE NOX1/4 INHIBITOR GKT831 ACHIEVES CLINICALLY MEANINGFUL REDUCTIONS IN LIVER STIFFNESS, ATTENUATES CHOLESTASIS, AND IMPROVES QUALITY OF LIFE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (2019) Huang JC, Invernizzi P, Dalekos GN, Nevens F, Van Vlierberghe H, Zigmond E, Andrade RJ, et al. Conference contribution CLINICAL AND VIROLOGICAL CHARACTERISTICS AND RETREATMENT OF HCV-INFECTED PATIENTS WITH FAILURE TO MULTIPLE SUBSEQUENT DAA THERAPIES (2019) Dietz J, Vermehren J, Peiffer KH, Wietzke-Braun P, Muellhaupt B, Schattenberg J, Antoni C, et al. Conference contribution Bile salt subspecies activate MRGX4 expressed on sensory neurons and cause itching in humans (2019) Wolf K, Kühn H, Leibl V, Gebhardt L, Glaudo M, Reeh P, Fischer MJM, et al. Conference contribution Zooming in on liver zonation (2018) Felmlee DJ, Gruen D, Baumert TF Journal article Efficacy and Safety of Seladelpar, a Selective Peroxisome Proliferator-Activated Receptor Delta Agonist, in Primary Biliary Cholangitis: 52-Week Analysis of an Ongoing International, Randomized, Dose Ranging Phase 2 Study (2018) Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, Kremer A, et al. Conference contribution Effect of Seladelpar on Pruritus in Primary Biliary Cholangitis: 26-Week Analysis of an Ongoing International, randomized, Dose Ranging Phase 2 Study (2018) Kremer A, Bowlus CL, Neff GW, Aspinall R, Galambos MR, Goel A, Hirschfield G, et al. Conference contribution
1 2 3